3 Horrendous Healthcare Stocks This Week 3-28-14

  • 11,839 views
Uploaded on

This week's most horrendous healthcare stocks.

This week's most horrendous healthcare stocks.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
11,839
On Slideshare
0
From Embeds
0
Number of Embeds
14

Actions

Shares
Downloads
12
Comments
0
Likes
4

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

Transcript

  • 1. 3 Horrendous Health-Care Stocks This Week
  • 2. Has the so-called biotech bubble burst? Two of this week’s most horrendous health-care stocks bolster the theory, while the third stock could simply be experiencing the effects of market gravity. Source: Wikimedia Commons
  • 3. The biotech’s shares plunged more than 46% for the week. Exelixis (Nasdaq: EXEL) Source: Yahoo! Finance
  • 4. • It announced on Tuesday the completion of an interim analysis of Cometriq and that the phase 3 prostate cancer trial would continue to final analysis. • Many observers expected the study would be stopped early, as Johnson & Johnson’s Zytiga and Medivation’s Xtandi were. • Exelexis expects top-line data from the phase 3 study later this year. Why Exelixis got clobbered
  • 5. Shares of the cloud-based health-care technology company dropped 27% this week. Castlight Health (NYSE: CSLT) Source: Yahoo! Finance
  • 6. • Castlight’s IPO was last week, with the stock vaulting nearly 150% on its first day of trading. • With only $13 million in revenue, Castlight’s market cap hit $3 billion. • The backlash is apparently now under way, with plenty of critics. • Yahoo! Finance called Castlight the “most overpriced IPO of the century.” Why Castlight’s stock careened
  • 7. The stock of the biopharmaceutical company fell 24% this week. Galena Biopharma (Nasdaq: GALE) Source: Yahoo! Finance
  • 8. • This week’s decline appears to be a continuation from last week’s announcement of an SEC investigation. • The investigation stems from alleged questionable stock-promotions efforts by The DreamTeam Group, particularly involving the posting of positive articles about Galena. • Several online financial sites, including The Motley Fool, pulled articles related to the controversy over the past few months. Why Galena shares dropped
  • 9. • While Castlight’s business model is compelling, the stock really is overpriced right now. • Galena could certainly come back with good news from cancer immunotherapy Neuvax. • Exelixis gets the nod as the most likely to rebound. • Continuation of the Cometriq study was disappointing, but the market overreacted, in my view. Best shot at bouncing back?
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!